Home Newsfeeds Wedbush Reiterates Outperform on Microsoft, Maintains $280 Price Target

Wedbush Reiterates Outperform on Microsoft, Maintains $280 Price Target

Wedbush analyst Daniel Ives reiterates Microsoft (NASDAQ:MSFT) with a Outperform and maintains $280 price target.

byBenzinga Newsdesk

February 8, 2023

1 minute read

Wedbush analyst Daniel Ives reiterates Microsoft (NASDAQ:MSFT) with a Outperform and maintains $280 price target.

$100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today

By Benzinga Insights

September 5, 1:00 PM

Cognizant Tech Solns (NASDAQ:CTSH) has outperformed the market over the past 15 years by 2.51% on an annualized…

CTSH

Beam Therapeutics’ Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy

By Vandana Singh

September 5, 1:58 PM

Beam Therapeutics Inc (NASDAQ: BEAM) announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic

BEAM

News

QualTek To Deploy Storm Resources In Response To Hurricane Ian

By Benzinga Newsdesk

September 29, 9:00 AM

BLUE BELL, Pa., Sept. 29, 2022 /PRNewswire/ -- QualTek Services Inc. ("QualTek" or the "Company") (NASDAQ:QTEK), a leading turnkey provider of infrastructure services to the North

QTEK

One Credit Suisse Analyst Says Bank’s Capital, Liquidity ‘Healthy,’ Another Warns Of Impending Equity Raise: What You Need To Know

By Adam Eckert

October 3, 1:05 PM

Credit Suisse Group (NYSE: CS) is dominating headlines Monday morning amid rising concerns over the Swiss bank's financial health.

Wedbush Reiterates Outperform on Microsoft, Maintains $280 Price Target

Related Posts

$100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today

Beam Therapeutics’ Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy

QualTek To Deploy Storm Resources In Response To Hurricane Ian

One Credit Suisse Analyst Says Bank’s Capital, Liquidity ‘Healthy,’ Another Warns Of Impending Equity Raise: What You Need To Know